TITLE

Olanzapine case

AUTHOR(S)
Sibbald, Barbara
PUB. DATE
August 2005
SOURCE
CMAJ: Canadian Medical Association Journal;8/2/2005, Vol. 173 Issue 3, p243
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the decision of pharmaceutical firm Eli Lilly and Co. to settle claims related to the adverse effect of olanzapine, an atypical antipsychotic medication used to treat schizophrenia and bipolar disorder. Adverse effects of the drug; Reason behind the decision of the company; Value of the sales of the drug in 2003.
ACCESSION #
17679345

 

Related Articles

  • FDA APPROVES LILLY'S ZYPREXA RELPREVV FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS.  // Psychiatry (1550-5952);Dec2009, Vol. 6 Issue 12, p9 

    The article reports on the U.S. Food and Drug Administration's (FDA) approval of the extended-release injectable suspension drug Zyprexa Relprevv from Eli Lilly & Co. for the treatment of schizophrenia in adult patients. It notes that Zyprexa Relprevv is a long acting formulation that can last...

  • Lilly, other drug firms fighting schizophrenia.  // Indianapolis Business Journal;07/20/98, Vol. 19 Issue 18, p30A 

    Features the Zyprexa drug for schizophrenics from Eli Lilly and Co. Indications of the drug; Cost of Zyprexa; Cost of treating schizophrenia; Statistics on schizophrenia in the United States; Side effects of antipsychotic drugs.

  • Ivax Begins Generics Battle Over Eli Lilly's Zyprexa. Krause, Carey // Chemical Market Reporter;03/05/2001, Vol. 259 Issue 10, p9 

    Reports on the plan of Ivax Corporation to file an abbreviated new drug application with the United States Federal Food and Drug Administration (FDA) to market a generic version of Zyprexa olanzapine antipsychotic drug of Eli Lilly company. Sales of Zyprexa in 2000; Patents held by Eli Lilly...

  • Eli Lilly: trial data may not prevent Zyprexa slide.  // PharmaWatch: Monthly Review;Feb2005, Vol. 4 Issue 2, p16 

    The article reports on the results of a non-randomized study which shows that one year medication of antipsychotic Zyprexa can reduce possible violent behavior on schizophrenia-spectrum disorder patients. This was in relation to the clinical trials conducted by the Schizophrenia Care and...

  • Lilly's antipsychotic axe will shift attention to Roche.  // PharmaWatch: CNS;Oct2012, Vol. 11 Issue 10, p11 

    The article reports that the development of Eli Lilly's pipeline glutamate receptor agonist, pomaglumetad methionil, in schizophrenia has been discontinued after a confirmed lack of efficacy. The company also announced that a mid-stage study of the drug as an add-on to common atypical...

  • Poles apart. Healy, David // New Scientist;4/15/2006, Vol. 189 Issue 2547, p38 

    The article focuses on claims made for "mood stabilising" drugs and the evidence for their safety and effectiveness. According to psychiatrist David Healy, who helped uncover the suicide risks associated with modern antidepressants, feels that they are more harmful to children. Many...

  • EU Lilly pays record fines of $1.4bn for promoting off-label use of olanzapine for common disorders. Kmietowicz, Zosia // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/24/2009, p191 

    The article reports that drug maker Eli Lilly has agreed to pay $1.4 billion in the settlement of a lawsuit for off-use marketing of its antipsychotic drug olanzapine (Zyprexa). The company's sales department promoted the drug licensed for treating schizophrenia and bipolar disorder for several...

  • Neurodevelopment and Mood Stabilizers. A. J. Harwood // Current Molecular Medicine;Aug2003, Vol. 3 Issue 5, p472 

    Mood disorders and schizophrenia share a number of common properties, including: genetic susceptibility; differences in brain structure and drug based therapy. Some genetic loci may even confer susceptibility for bipolar mood disorder and schizophrenia, and some atypical antipsychotic drugs are...

  • Teva: lining up Lilly.  // PharmaWatch: CNS;May 2005, Vol. 4 Issue 5, p9 

    Reports on the approval of Teva Pharmaceutical's olanzapine tablets which is subject to the U.S. District Court finding Eli Lilly's Zyprexa patent invalid. U.S. Food and Drug Administration's tentative approval of Teva's Abbreviated New Drug Application for a generic version of Eli Lilly's...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics